ArticleEndocrine connections2023
Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA.
Article in Endocrine connections, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of Sex and Deprivation on Neuroendocrine Tumour Survival: Challenges of Heterogeneous Data.Neuroendocrinology · 2025Pooled it
- Growth hormone-releasing hormone, growth hormone, and neuroendocrine tumors.Journal of clinical & translational endocrinology · 2026Review
- Head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2026Article
- Infiltrating Presacral Neuroendocrine Tumor: An Atypical Cause of Lower Gastrointestinal Bleeding.ACG case reports journal · 2026Article
- Real-World Effectiveness of Capecitabine and Temozolomide Across Endocrine and Neuroendocrine Neoplasm Subtypes (ENENs): A Population-Based Cohort Study from Alberta, Canada (2011-2021).Current oncology (Toronto, Ont.) · 2026Article
- A rare indolent neuroendocrine tumor of the left intrahepatic bile duct: a case report emphasizing early detection.International journal of surgery case reports · 2026Article
- Clinicopathological Characteristics and Survival Outcomes of Gastrointestinal Neuroendocrine Tumors in a Large Safety Net Hospital.Journal of clinical medicine · 2026Article
- Connecting systemic inflammation to prognosis in neuroendocrine neoplasms: a biomarker-based approach.Frontiers in medicine · 2026Article
- The impact of radioligand therapy on prognosis in patients with lung neuroendocrine tumors.Frontiers in endocrinology · 2026Article
- Overlapping Presentations and Diverse Genetic Defects Characterize Neuroendocrine Neoplasms in a Mexican Cohort.The Journal of clinical endocrinology and metabolism · 2025Article
- Analysis of clinicopathological characteristics and prognosis of appendiceal neuroendocrine tumors: a retrospective cohort study based on the SEER database.Translational cancer research · 2025Article
- Beyond similarities: overall survival and prognostic insights from [¹⁷⁷Lu]Lu-DOTATOC therapy in neuroendocrine tumors.European journal of nuclear medicine and molecular imaging · 2025Article
- The Silent Presentation of a Non-functioning Pancreatic Neuroendocrine Tumor: A Case Report.Cureus · 2025Article
- Neuroendocrine Neoplasms in Pregnancy: A Narrative Review of Clinical Challenges and Therapeutic Limitations in the Absence of Established Safe Treatments.Journal of personalized medicine · 2025Review
- Last decade of advances in gastric neuroendocrine tumors: Innovations, challenges, and future directions.World journal of clinical oncology · 2025Article
- Article
- Prodrugs in Oncology: Bioactivation and Impact on Therapeutic Efficacy and Toxicity.International journal of molecular sciences · 2025Review
- Review
- Prognosis of NETs: Has There Been Improvement over the Last 30 Years?Neuroendocrinology · 2025Review
- Epidemiological insights and survival patterns in neuroendocrine neoplasia: a geographic perspective.Endocrine oncology (Bristol, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Updated epidemiological data of neuroendocrine tumors are currently lacking. Thus, we performed epidemiological and survival analyses on a large cohort of patients with neuroendocrine tumors and developed a new nomogram to predict survival. Methods: This population-based study examined 112,256 patients with neuroendocrine tumors between 2000 and 2018 using data from the Surveillance, Epidemiology, and End Results program. Results: The age-adjusted incidence per 100,000 persons of neuroendocrine tumors increased from 4.90 in 2000 to 8.19 in 2018 (annual percentage change, 3.40; 95% confidence interval, 3.13-3.67), with the most significant increases in grade 1, localized stage, and appendix neuroendocrine tumors. The age-adjusted mortality rate increased 3.1-fold from 2000 to 2018 (annual percentage change, 4.14; 95% confidence interval, 3.14-5.15). The 1-, 5-, and 10-year relative survival rates for all neuroendocrine tumors were 80.5%, 68.4%, and 63.5%, respectively. Multivariate analyses showed that male sex; older age; Black, American Indian, and Alaska Native populations; earlier year of diagnosis; lung neuroendocrine tumors; higher grades; and later stage were associated with a worse prognosis and that disease stage and grade were the most important risk factors for prognosis. Furthermore, we established a nomogram to predict the 3-, 5-, and 10-year survival rates, and its discrimination ability was better than that of the TNM classification. Conclusions: The incidence, prevalence, and mortality rate of neuroendocrine tumors continued to increase over the last two decades. Additionally, the nomogram could accurately quantify the risk of death in patients with neuroendocrine tumors and had good clinical practicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.